Mefloquine
Lariam (mefloquine) is a small molecule pharmaceutical. Mefloquine was first approved as Lariam on 1989-05-02. It is used to treat falciparum malaria, malaria, and vivax malaria in the USA. It is known to target adenosine receptor A1 and adenosine receptor A2a.
Download report
Favorite
COVID-19
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
infections | D007239 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
mefloquine hydrochloride | ANDA | 2023-02-16 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
falciparum malaria | EFO_0007444 | D016778 | B50 |
malaria | EFO_0001068 | D008288 | B54 |
vivax malaria | EFO_0007445 | D016780 | B51 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
54 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Malaria | D008288 | EFO_0001068 | B54 | 2 | 6 | 10 | 6 | 5 | 26 |
Falciparum malaria | D016778 | EFO_0007444 | B50 | 1 | 5 | 9 | 3 | 6 | 20 |
Healthy volunteers/patients | — | 1 | — | — | 1 | — | 2 | ||
Parasitic diseases | D010272 | EFO_0001067 | B88 | — | — | — | 1 | — | 1 |
Vivax malaria | D016780 | EFO_0007445 | B51 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 1 | — | 3 | 4 |
Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | 1 | 1 | — | 1 | 2 |
Schistosoma haematobium | D012548 | — | — | 1 | — | — | 1 | ||
Schistosoma mansoni | D012550 | NCBITaxon_6183 | — | — | 1 | — | — | 1 | |
Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | 1 | 1 | — | — | 1 |
Viral pneumonia | D011024 | EFO_0007541 | J12.9 | — | 1 | 1 | — | — | 1 |
Covid-19 | D000086382 | U07.1 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | 1 | — | — | — | 1 |
Schistosomiasis haematobia | D012553 | EFO_0007530 | B65.0 | — | 1 | — | — | — | 1 |
Progressive multifocal leukoencephalopathy | D007968 | EFO_0007455 | A81.2 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Glioblastoma | D005909 | EFO_0000515 | 1 | — | — | — | — | 1 | |
Gliosarcoma | D018316 | 1 | — | — | — | — | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | MEFLOQUINE |
INN | mefloquine |
Description | (-)-(11S,2'R)-erythro-mefloquine is an optically active form of [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol having (-)-(11S,2'R)-erythro-configuration. An antimalarial agent, used in racemic form, which acts as a blood schizonticide; its mechanism of action is unknown. It has a role as an antimalarial. It is an enantiomer of a (+)-(11R,2'S)-erythro-mefloquine. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | OC(c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)C1CCCCN1 |
Identifiers
PDB | — |
CAS-ID | 49752-90-1 |
RxCUI | — |
ChEMBL ID | CHEMBL416956 |
ChEBI ID | 63681 |
PubChem CID | 40692 |
DrugBank | DB00358 |
UNII ID | TML814419R (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,192 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
16 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more